ACE and breast cancer: Therefore, these results suggest possible inflammatory-reducing benefits of CAP–EPA combination in triple-negative breast cancer (TNBC) MDA-MB-231 cells but not in MCF-7 cells, indicating the potential role of n-3 PUFAs and antihypertensive ACE inhibitors in attenuating the tumor-promoting proinflammatory effects of adipocytes on breast cancer cells.